Clinical Edge Journal Scan

Sugar-sweetened beverage and sugar consumption tied with incidence of and mortality from proximal colon cancer


 

Key clinical point: High sugar-sweetened beverage (SSB) and total fructose intake was associated with increased incidence of and mortality from proximal colon cancer, especially during the later stages of colorectal tumorigenesis.

Major finding: SSB and total fructose consumption was associated with a significant increase in the incidence of (hazard ratio [HR] per 1-serving/d increment 1.18 and HR per 25-g/d increment 1.18, respectively; both Ptrend = .02) and mortality from (HR 1.39; Ptrend = .002 and HR 1.42; Ptrend = .003, respectively) proximal colon cancer.

Study details: This large-scale study included 121,111 adult health professionals from two US prospective cohorts, the Nurses’ Health Study and Health Professionals Follow-Up Study.

Disclosures: The study was sponsored by grants from the US National Institutes of Health, American Cancer Society, and American Institute for Cancer Research. Some authors declared consulting and advisory board participation for and receiving research funds from various sources.

Source: Yuan C et al. Sugar-sweetened beverage and sugar consumption and colorectal cancer incidence and mortality according to anatomic subsite. Am J Clin Nutr. 2022 (Apr 25). Doi: 10.1093/ajcn/nqac040

Recommended Reading

Unresectable mCRC: Final survival outcomes with first-line trifluridine/tipiracil plus bevacizumab in TASCO1
MDedge Hematology and Oncology
Proton pump inhibitors curb capecitabine efficacy in stage II-III CRC
MDedge Hematology and Oncology
Proton pump inhibitors curb capecitabine efficacy in stage II-III CRC
MDedge Hematology and Oncology
Survival after CRS-HIPEC in synchronous vs metachronous peritoneal metastasis of CRC
MDedge Hematology and Oncology
Can proximal serrated polyp detection rate serve as an indicator for interval post-colonoscopy CRC?
MDedge Hematology and Oncology
Can proximal serrated polyp detection rate serve as an indicator for interval post-colonoscopy CRC?
MDedge Hematology and Oncology
Evidence supporting initiation of CRC screening before 50 years of age in women
MDedge Hematology and Oncology
KRAS p.G12C mutations may have prognostic implications in mCRC
MDedge Hematology and Oncology
ctDNA: Strong prognostic biomarker but lacks true clinical utility in mCRC
MDedge Hematology and Oncology
ctDNA: Strong prognostic biomarker but lacks true clinical utility in mCRC
MDedge Hematology and Oncology